DAX19.405 +0,4%ESt504.800 +0,2%MSCIW3.777 -0,1%Dow44.737 +1,0%Nas19.055 +0,3%Bitcoin90.216 +1,4%Euro1,0479 -0,2%Öl73,14 +0,1%Gold2.621 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T MicroStrategy 722713 Rheinmetall 703000 Siemens Energy ENER6Y Commerzbank CBK100 Super Micro Computer A40MRM Bayer BAY001 RENK RENK73 Deutsche Telekom 555750 Palantir A2QA4J EVOTEC 566480 Volkswagen (VW) vz. 766403 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Asiens Börsen uneinheitlich -- Zoom enttäuscht mit Gewinnplus -- BVB im Fokus
Top News
QUALCOMM-Aktie in Rot: Interesse an Intel-Übernahme schwindet anscheinend QUALCOMM-Aktie in Rot: Interesse an Intel-Übernahme schwindet anscheinend
Roche-Aktie: Übernahme von Poseida Therapeutics - Primäres Studienziel bei Lungenkrebs-Kombitherapie verfehlt Roche-Aktie: Übernahme von Poseida Therapeutics - Primäres Studienziel bei Lungenkrebs-Kombitherapie verfehlt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

INNATE PHARMA SA Aktie

NeuKaufenVerkaufen
1,41 EUR -0,12 EUR -7,62 %
FSE
1,43 EUR -0,10 EUR -6,79 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.124,01 Mio. EUR

Div. Rendite0,00%

WKNA0LCUJ

ISINFR0010331421

SymbolIPHYF

INNATE PHARMA SA Aktien News

DatumMeistgelesen
BusinesswireInnate Pharma Provides Update on Silicon Valley Bank Exposure
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of February 1, 2023
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireInnate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
BusinesswireInnate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
BusinesswireSanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
BusinesswireInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of December 1, 2022
BusinesswireInnate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
BusinesswireInnate Pharma Reports Third Quarter Financial Results
BusinesswireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
BusinesswireInnate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireInnate Pharma 2023 Financial Calendar
BusinesswireInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
BusinesswireInnate Pharma Reports First Half 2022 Financial Results and Business Update
BusinesswireInnate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
BusinesswireInnate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of August 1, 2022
BusinesswireInnate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
BusinesswireInnate Pharma to Participate in Upcoming Investor Conference
BusinesswireSecond Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
BusinesswireInnate Pharma to Participate in Upcoming Investor Conference
BusinesswireInnate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
BusinesswireOutcome of Innate Pharma’s 2022 Annual General Meeting
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireInnate Pharma Reports First Quarter 2022 Financial Results and Business Update
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of May 1, 2022
BusinesswireInnate Pharma Establishes an At-The-Market ("ATM”) Program on Nasdaq
BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
BusinesswireInnate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
BusinesswireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
BusinesswireInnate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
BusinesswireInnate Pharma Reports Full Year 2021 Financial Results and Business Update
BusinesswireInnate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of March 1, 2022
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of February 1, 2022
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2022

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.